Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTRANS vs DEMEROL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
Meperidine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia, sedation, and euphoria. It also has additional weak actions at kappa and delta receptors.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Treatment of opioid dependence (as part of medication-assisted treatment)
Moderate to severe pain,Preoperative analgesia,Anesthesia adjunct,Obstetrical analgesia
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
50-150 mg IM, IV, or SC every 3-4 hours as needed for pain; oral 50-150 mg every 3-4 hours.
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
2.5-4 hours; prolonged in hepatic impairment (7-11 hours) and elderly.
Primarily metabolized by CYP3A4 to norbuprenorphine; also undergoes conjugation with glucuronic acid. Norbuprenorphine is active and further glucuronidated.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution and consider starting at the lowest dose (5 mcg/h) with close monitoring for adverse effects.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 75% of dose; GFR <10 m L/min: administer 50% of dose.
Risk of respiratory depression, addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome; risk of potentially fatal respiratory depression when used with benzodiazepines or other CNS depressants; and risk of life-threatening respiratory depression in children with accidental ingestion.
First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS); avoid chronic use near term due to risk of respiratory depression. Generally, buprenorphine is considered lower risk than full agonists but still requires careful risk-benefit assessment.
Pregnancy Category C. First trimester: No well-controlled studies; potential risk based on animal studies showing increased skeletal malformations at high doses. Second trimester: Risk of fetal dependence and withdrawal if used chronically. Third trimester: Use near term may cause neonatal respiratory depression, withdrawal syndrome (irritability, tremors, poor feeding), and reduced uterine tone leading to prolonged labor.
BUTRANS (buprenorphine transdermal system) is a Schedule III partial mu-opioid agonist used for chronic pain. Do not apply to irritated skin; rotate application sites to minimize skin reactions. Onset of analgesia is delayed (12-24 hours), so titrate with immediate-release analgesics as needed. Avoid concurrent use with full mu-opioid agonists (e.g., morphine) due to risk of precipitated withdrawal. The 5, 7.5, 10, 15, and 20 mcg/h patches are approved; 20 mcg/h is the maximum single dose. Reserve for patients tolerant to around-the-clock opioids (≥30 mg oral morphine equivalents/day). Monitor for respiratory depression (less than full agonists, but still a risk) and serotonin syndrome with other serotonergic agents.
Meperidine (Demerol) is contraindicated in patients with renal impairment due to accumulation of normeperidine, a neurotoxic metabolite that can cause seizures. Avoid use for >48 hours or doses >600 mg/day. It has a shorter duration of action than morphine and is less effective for severe pain. Serotonin syndrome risk is high when combined with other serotonergic drugs. Do not administer IV if patient has taken MAO inhibitor within 14 days (can cause hyperpyrexia, hypotension, death).
No interactions on record
No interactions on record
BUTRANS and DEMEROL are distinct pharmacological agents. BUTRANS belongs to the Opioid Analgesic class and is primarily used for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequateTreatment of opioid dependence (as part of medication-assisted treatment). DEMEROL belongs to the Opioid Analgesic class and is primarily used for Moderate to severe painPreoperative analgesiaAnesthesia adjunctObstetrical analgesia. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. BUTRANS carries a safety status of Category C, whereas DEMEROL safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via hydrolysis to meperidinic acid and N-demethylation to normeperidine (active metabolite) by CYP3A4 and CYP2B6.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal (90% as metabolites and unchanged drug; ~5% unchanged) and biliary/fecal (minor).
96% bound primarily to albumin and alpha-1-acid glycoprotein
65-75% bound (primarily to alpha1-acid glycoprotein and albumin)
Vd: 2-5 L/kg, indicating extensive tissue distribution
2.4-3.7 L/kg; large due to extensive tissue distribution
Transdermal: 15-25%; buccal: 60-70%
Oral: 50-60% (first-pass metabolism); IM: ~75%
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Start at the lowest dose (5 mcg/h) and titrate cautiously; consider reducing dose by 50%. Child-Pugh Class C: Avoid use due to increased risk of toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not recommended for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
1-2 mg/kg IM, IV, or SC every 3-4 hours (max 100 mg/dose); oral 1-2 mg/kg every 3-4 hours.
Initiate at the lowest dose (5 mcg/h) and titrate slowly with careful monitoring for respiratory depression, sedation, and falls. Consider age-related reductions in renal and hepatic function.
Lower initial doses (25-50 mg) with extended intervals (every 4-6 hours); monitor for respiratory depression and CNS effects.
Risk of respiratory depression; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of medication errors leading to accidental overdose; risk of serotonin syndrome if used with serotonergic drugs; risk of adrenal insufficiency.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; risk with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizures; biliary tract disease; use in elderly and debilitated patients; hepatic impairment; renal impairment; pregnancy; lactation.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially increasing buprenorphine levels. No other significant food interactions documented.
Avoid alcohol consumption; may enhance CNS depression. No significant food interactions known.
Buprenorphine is excreted into breast milk. M/P ratio approximately 0.3 (range 0.1-0.6). Relative infant dose about 1-2% of maternal weight-adjusted dose. Monitor infant for sedation, respiratory depression, and withdrawal if breastfeeding is initiated or discontinued. Generally compatible with breastfeeding in stable patients.
Meperidine excreted into breast milk with M/P ratio approximately 1.0. Breastfeeding not recommended due to risk of neonatal CNS depression and accumulation of active metabolite normeperidine. Avoid use if breastfeeding; if necessary, monitor infant for sedation and poor feeding.
No routine dose adjustment recommended. However, increased clearance in pregnancy may require dose titration based on clinical response. Monitor for withdrawal symptoms as pregnancy progresses; dose may need to be increased. Postpartum, dose may need to be reduced due to restored clearance.
Pharmacokinetics altered in pregnancy: increased volume of distribution and clearance. Dose adjustment not typically recommended for routine pain management, but lower doses may be required in third trimester due to enhanced CNS sensitivity. Use lowest effective dose for shortest duration. Avoid high doses or prolonged use due to neonatal withdrawal risk.
Apply the patch to clean, dry, hairless skin on the upper arm, chest, back, or side of the chest. Remove immediately if it falls off.,Wear the patch for 7 days; replace with a new patch at the same time of day. Do not cut or damage the patch.,Avoid exposure to direct heat (heating pads, saunas, hot tubs, prolonged sun) as it increases absorption and overdose risk.,Do not drink alcohol while using Butrans; it can cause dangerous side effects.,Keep all patches away from children and pets; used patches should be folded and flushed down the toilet immediately.,Do not stop abruptly or change dose without consulting your doctor; withdrawal may occur.,Common side effects include nausea, constipation, headache, and application site redness.
Do not drink alcohol while taking this medication.,Avoid driving or operating machinery until you know how the medication affects you.,Do not increase your dose or frequency without consulting your doctor.,Report any symptoms of serotonin syndrome: agitation, hallucinations, rapid heart rate, fever, muscle stiffness, twitching, nausea, vomiting, diarrhea.,This medication may cause constipation; increase fluid intake and fiber.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur.,Store at room temperature, away from light and moisture.